Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles J L la Porte

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|September 10, 2009
Saquinavir, the pioneer antiretroviral protease inhibitorCharles J L la Porte
AIDS Patient Care and Stds|September 26, 2012
Surreptitious antiretroviral use as an explanation for apparent elite HIV controlCecilia T Costiniuk, Charles J L La Porte, Jonathan B Angel
AIDS (London, England)|February 5, 2011
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumoniaJunine Toy, Pierre Giguère, Stephen Kravcik, et al.
The Canadian Journal of Hospital Pharmacy|April 6, 2012
Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practiceNiamh Higgins, Alice Tseng, Nancy L Sheehan, et al.
Therapeutic Drug Monitoring|April 22, 2006
False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampinCharles J L la Porte, Jacqueline A H Droste, David M Burger
Antimicrobial Agents and Chemotherapy|November 19, 2008
Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteersCharles J L la Porte, John P Sabo, Mabrouk Elgadi, et al.
The Annals of Pharmacotherapy|December 4, 2009
Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adultAmanda Caroline Jacques, Pierre Giguère, Guijun Zhang, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 30, 2011
Medication-based urolithiasis and atazanavirPaul M Koblic, Wayne L Gold, Charles J L la Porte, et al.
The Journal of Antimicrobial Chemotherapy|July 20, 2010
Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohortDaniel F Carr, Charles J L la Porte, Munir Pirmohamed, et al.
Therapeutic Drug Monitoring|November 23, 2012
Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptorClaudia P Cortes, Marco Siccardi, Ammara Chaikan, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Metabolism & Toxicology|September 10, 2009
Saquinavir, the pioneer antiretroviral protease inhibitorCharles J L la Porte
AIDS Patient Care and Stds|September 26, 2012
Surreptitious antiretroviral use as an explanation for apparent elite HIV controlCecilia T Costiniuk, Charles J L La Porte, Jonathan B Angel
AIDS (London, England)|February 5, 2011
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumoniaJunine Toy, Pierre Giguère, Stephen Kravcik, et al.
The Canadian Journal of Hospital Pharmacy|April 6, 2012
Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practiceNiamh Higgins, Alice Tseng, Nancy L Sheehan, et al.
Therapeutic Drug Monitoring|April 22, 2006
False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampinCharles J L la Porte, Jacqueline A H Droste, David M Burger
Antimicrobial Agents and Chemotherapy|November 19, 2008
Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteersCharles J L la Porte, John P Sabo, Mabrouk Elgadi, et al.
The Annals of Pharmacotherapy|December 4, 2009
Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adultAmanda Caroline Jacques, Pierre Giguère, Guijun Zhang, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 30, 2011
Medication-based urolithiasis and atazanavirPaul M Koblic, Wayne L Gold, Charles J L la Porte, et al.
The Journal of Antimicrobial Chemotherapy|July 20, 2010
Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohortDaniel F Carr, Charles J L la Porte, Munir Pirmohamed, et al.
Therapeutic Drug Monitoring|November 23, 2012
Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptorClaudia P Cortes, Marco Siccardi, Ammara Chaikan, et al.
Pageof 2